Contrary to expectation, however, KRAS mutation status does not correlate with increased sensitivity to anti-mitotic agents when analysing a small in-house panel of cancer cell lines, three isogenic cell line pairs or a large database of anti-cancer drug responses. Here, KRAS is linked to cancer.